Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyTrebananib
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Trebananib
- Accession Number
- DB12056
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Description
Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon Cancer, among others.
- Protein chemical formula
- Not Available
- Protein average weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Not Available
- External IDs
- Amg 386
- Categories
- UNII
- X8Y5U6NC7E
- CAS number
- 894356-79-7
Pharmacology
- Indication
- Not Available
- Structured Indications
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Trebananib. Approved Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Trebananib. Experimental Ancestim The risk or severity of cytotoxicity can be increased when Ancestim is combined with Trebananib. Approved, Investigational, Withdrawn Bevacizumab Bevacizumab may increase the cardiotoxic activities of Trebananib. Approved, Investigational Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trebananib. Approved Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Trebananib. Approved, Investigational Cymarin Cymarin may decrease the cardiotoxic activities of Trebananib. Experimental Deslanoside Deslanoside may decrease the cardiotoxic activities of Trebananib. Approved Digitoxin Digitoxin may decrease the cardiotoxic activities of Trebananib. Approved, Investigational Digoxin Digoxin may decrease the cardiotoxic activities of Trebananib. Approved Digoxin Immune Fab (Ovine) Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Trebananib. Approved Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Trebananib. Approved, Investigational Gitoformate Gitoformate may decrease the cardiotoxic activities of Trebananib. Experimental Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Trebananib. Experimental Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Trebananib. Experimental Oleandrin Oleandrin may decrease the cardiotoxic activities of Trebananib. Experimental, Investigational Ouabain Ouabain may decrease the cardiotoxic activities of Trebananib. Approved Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Trebananib. Approved, Vet Approved Peruvoside Peruvoside may decrease the cardiotoxic activities of Trebananib. Experimental Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Trebananib. Experimental Trastuzumab Trastuzumab may increase the cardiotoxic activities of Trebananib. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911276
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Taxonomy
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Drug created on October 20, 2016 15:16 / Updated on March 02, 2018 04:05